{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:17:08Z","timestamp":1790806628096,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23lk0221173h0001"],"award-info":[{"award-number":["23lk0221173h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Previously, we conducted the phase I study of 64Cu-ATSM, which is Cu-diacetyl-bis (N4-methylthiosemicarbazone) radiolabeled with Cu-64, for patients with brain tumors and determined the maximum tolerated dose. We started a subsequent multicenter, randomized, open-label phase III study to evaluate the efficacy of 64Cu-ATSM as an investigator-initiated registration-directed trial for recurrent or residual malignant glioma (protocol No. NCCH2301, STEP-64). Patients will be randomized to either the control or study arm (64Cu-ATSM). A large-scale randomized trial seems difficult to perform for patients with brain tumors because of small sample sizes. Therefore, we designed a small randomized trial with 56 patients. Furthermore, as a pragmatic approach in the control arm, physicians can choose treatments depending on the patient\u2019s condition among the clinically available options, where the drugs used are not regarded as investigational. The trial was registered in the Japan Registry of Clinical Trials as jRCT2031240090.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf026","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T12:44:20Z","timestamp":1740660260000},"page":"543-546","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0349-0832","authenticated-orcid":false,"given":"Yayoi","family":"Ando","sequence":"first","affiliation":[{"name":"Research Management Division, Clinical Research Support Office, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8031-4306","authenticated-orcid":false,"given":"Makoto","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Kanagawa Cancer Center , 2-3-2, Nakao, Asahi-ku, Yokohama-city, Kanagawa 241-8515,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiteru","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ichimura","sequence":"additional","affiliation":[{"name":"Research Management Division, Clinical Research Support Office, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Anjo","sequence":"additional","affiliation":[{"name":"Research Management Division, Clinical Research Support Office, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Inaba","sequence":"additional","affiliation":[{"name":"Research Management Division, Clinical Research Support Office, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Data Management Division, Clinical Research Support Office, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sadachi","sequence":"additional","affiliation":[{"name":"Biostatistics Division, Center for Research Administration and Support, National Cancer Center ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibata","sequence":"additional","affiliation":[{"name":"Biostatistics Division, Center for Research Administration and Support, National Cancer Center ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Okita","sequence":"additional","affiliation":[{"name":"Research Management Division, Clinical Research Support Office, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of International Clinical Development\/Clinical Research Support Office, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Isotope Science Center, The University of Tokyo , 2-11-16, Yayoi, Bunkyo-ku, Tokyo 113-0032,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Yoshii","sequence":"additional","affiliation":[{"name":"LinqMed Inc , 3-11-5, Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-6006","authenticated-orcid":false,"given":"Yoshitaka","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"2025042804271059300_ref1","volume-title":"National Cancer Center","author":"Rare Cancer Center","year":"2014"},{"key":"2025042804271059300_ref2","doi-asserted-by":"publisher","author":"The WHO classification of Tumors of the Central Nervous System","year":"2021","DOI":"10.1016\/j.mrrev.2021.108393"},{"key":"2025042804271059300_ref3","first-page":"1247","article-title":"Prognostic implication of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET\/CT in patients with glioma","volume":"36","author":"Toriihara","year":"2015","journal-title":"Ann Nucl Med"},{"key":"2025042804271059300_ref4","first-page":"263","article-title":"Hypoxia and the malignant glioma microenvironment: Regulation and implications for therapy","volume":"2","author":"Oliver","year":"2009","journal-title":"Curr Mol Pharmcol"},{"key":"2025042804271059300_ref5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tranon.2017.10.006","article-title":"Multiple administrations of 64Cu-ATSM as a novel therapeutic option for glioblastoma: A translational study using mice with xenografts","volume":"11","author":"Yoshii","year":"2018","journal-title":"Transl Oncol"},{"key":"2025042804271059300_ref6","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.tranon.2019.05.017","article-title":"Preclinical pharmacokinetic and safety studies of copper-Diacetyl-Bis(N4-Methylthiosemicarbazone) (Cu-ATSM): Translational studies for internal radiotherapy","volume":"12","author":"Matsumoto","year":"2019","journal-title":"Transl Oncol"},{"key":"2025042804271059300_ref7","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/JCO.2024.42.16_suppl.2052","article-title":"Phase I clinical trial of 64Cu-ATSM for the treatment of malignant brain tumors","volume":"42","author":"Kuriahra","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025042804271059300_ref8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jjco\/hyaa028","article-title":"Regulatory changes after the enforcement of the new clinical trials act in Japan","volume":"50","author":"Nakamura","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2025042804271059300_ref9","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025042804271059300_ref10","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1259\/bjr\/82292521","article-title":"Imaging hypoxia in gliomas","volume":"84","author":"Mendichovszky","year":"2011","journal-title":"Br J Radiol"},{"key":"2025042804271059300_ref11","author":"INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2)","year":"2016"},{"key":"2025042804271059300_ref12","volume-title":"Pharmaceuticals and Public Health Bureau, Revision of the Q&A Concerning Notification of Drug Clinical Trial Plans and Implementation of Clinical Trials","author":"Pharmaceutical Evaluation and Management Division","year":"2022"},{"key":"2025042804271059300_ref13","author":"GOOD CLINICAL PRACTICE (GCP) E6(R3)","year":"2023"},{"key":"2025042804271059300_ref14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/jjco\/hys121","article-title":"Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma","volume":"42","author":"Nagane","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"2025042804271059300_ref15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2307\/2530299","article-title":"Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint","volume":"38","author":"Schoenfeld","year":"1982","journal-title":"Biometrics"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/5\/543\/62278097\/hyaf026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/5\/543\/62278097\/hyaf026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:27:21Z","timestamp":1745828841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/5\/543\/8052677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,5]]},"published-print":{"date-parts":[[2025,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf026","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,5]]}}}